



-Maria Mandelkow, MD, PhD ociate Professor, Max-Planck Institute for Medical Rese



Our mission: Accelerating drug discovery for Alzheimer's disease through venture philanthropy.

Board of Directors

Leonard Lauder, Co-Chairperson, Chairman, Estée Lauder Companies Inc. Ronald Lauder, Co-Chairperson, Chairman, Clinique Laboratories Nancy Corzine, President, Owner & CEO, Nancy Corzine Howard Fillit, MD, Executive Director Suzanne Grossberg, Secretary, Director of External Affairs Joan Krupskas, Treasurer, Executive Director, Estée Lauder Companies John Cooney, Private Investor, Retired Insurance CEO Robert McNeil, PhD, Founder & Managing Director, Sanderling Ventures Jon Rotenstreich, Managing Partner, RF Partners, Founding Principal/Chairman, Bayer Properties Randal Sandler, Director, Client Service and Marketing, Bridgewater Associates Richard Schwartz, Chairman, New York State Council on the Arts Cyrus Vance, Jr., Partner, Morvillo, Abramowitz, Grand, Lason & Silberberg PC

Advisory Council

Carol Seabrook Boulanger, Partner, Pillsbury Winthrop Shaw Pittman LLP John Rowe, MD, Executive Chairman, Aetna, Inc. Andrew Schiff, MD, Managing Director, Aisling Capital Davia B. Temin, President, Temin and Company Incorporated Amy Treitel, Retired Financial Executive

Business Development Committee

Nancy Corzine, Chair, President Howard Fillit, MD, Executive Director Suzanne Grossberg, Director of External Affairs Monika Halarewicz, Communications and Events Manager Filomena Machleder, Partnership Relations Manager Anelle Miller, Design Consultant, Retired Senior Vice President, Design, Origins Kate Furman Pasik, Retired Finance & Real Estate Executive Liz Furman Sandler, Retired Attorney Leslye Sugar, Retired Public Relations Director, Johns Hopkins University Medical School

Staff

Howard Fillit, MD **Executive Director** 212.901-8001 HFillit@AlzDiscovery.org

Amy Treitel, Retired Financial Executive

Suzanne Grossberg Director of External Affairs 212.901.8008 SGrossberg@AlzDiscovery.org

Monika Halarewicz Communications and Events Manager 212.901-8003 MHalarewicz@AlzDiscovery.org

Antony Horton, PhD Director of Scientific Affairs 212.901.8007 AHorton@AlzDiscovery.org

Filomena Machleder Partnership Relations Manager 212.901.8004 FMachleder@AlzDiscovery.org

Wendy Ramos Grants and Database Manager 212.901.8005 WRamos@AlzDiscovery.org

Bryan Steros Deputy Director of Development 212.901.8009 BSteros@AlzDiscovery.org

Kerry Walsh **Executive Assistant** 212.901.8001 KWalsh@AlzDiscovery.org



Alzheimer's Drug Discovery Foundation 2006 ANNUAL HIGHLIGHTS



MESSAGE FROM THE FOUNDING EXECUTIVE DIRECTOR

ADDF is a very young organization, modifying drugs for Alzheimer's disease established only a bit more than are improving, with many compounds 2 years ago by the ISOA, a private now in human clinical trials. But despite foundation funded by the Estèe this progress, we still have so much Lauder Trust. As this report highlights, more to do. Our mission at ADDF is ADDF has advanced rapidly in a short to accelerate drug discovery for period of time, achieving its goal of Alzheimer's disease through biomedical enabling the public to work with us to venture philanthropy, so that loss of discover new drugs for Alzheimer's mind will no longer be the scourge of disease. Indeed, ADDF has already old age. I encourage you to participate demonstrated success in fundraising, with us to insure that we attain this partnerships and grant-making. We critical goal. are grateful to our partners for their trust and recognition of the value and importance of our efforts.

In the lifecycle of public charities, Today, the prospects for disease

Howard Fillit, MD

Discovery

THE ALZHEIMER'S DRUG DISCOVERY FOUNDATION (ADDF) IS ALL ABOUT SCIENCE. Building upon the highly focused mission and venture philanthropy investment model of its affiliated private foundation, the Institute for the Study of Aging (ISOA), the ADDF continued to support global scientists in their efforts to discover effective drugs for Alzheimer's disease (AD), related dementias and cognitive aging throughout 2006.

Unlike basic research that tries to understand the causes of a disease, drug discovery is an interdisciplinary process by which pills are created. It involves physicians, biologists, pharmacologists and medicinal chemists working together to screen chemicals, identify compounds, optimize their activity, and test them in the laboratory, animal models and human clinical trials. It is an extremely costly and time consuming process.

Traditional funding sources like foundations and government agencies tend to support basic research. Pharmaceutical and biotechnology companies favor financing later-stage drug development. Few sources support early-stage drug discovery, which has caused a major funding gap. ADDF and ISOA strive to fill this gap through venture philanthropy by awarding program related investment grants that enable them to receive a return on investment to fund more programs. Additionally, ADDF and ISOA staff continuously keep up with current research, proactively pursue scientists to apply for funding and provide them with technical assistance and resource networks to further their work.

In 2006, the ADDF and ISOA received a record 173 grant applications, the most applications received since their respective inceptions in 2004 and 1998. Of those, 35 were awarded funds totaling \$2,955,348, a 48% funding increase over 2005 thanks to many dedicated partners. Our second-year alliance with Elan Pharmaceuticals generated such exciting applications that we increased the number of awards for that program from 4 to 6. We also recovered payment on a convertible note awarded to Mindset Biopharmaceuticals in 2000.

Although it was a great year for advancing science, there were numerous requests that could not be funded due to limited dollars. Through establishing additional partnerships, the ADDF and ISOA could make an even greater impact on the field. Ultimately, supporting the discovery process leads to finding a cure.

2006 ADDF Contributing Partners: We gratefully acknowledge the following partners for their generosity and support. Through their dedication, we are able to advance our mission of accelerating drug discovery research.

Hope is on the horizon and it is being expedited by marrying smart business strategies with philanthropic giving.

Contributions of \$100,000 and above

Ms. Nancy Corzine Elan Pharmaceuticals, Inc.* Jack Parker Foundation Inc., Ms. Nancy Parker Magoon and Ms. Jane Ellen Parker Mrs. Cynthia Hazen Polsky

Contributions of \$10,000 and above Arie & Ida Crown Memorial

Athenagen, Inc. Robert E. and Dorothy Z. Barnhill Family Fund The Chisholm Foundation Mr. and Mrs. John P. Cooney

Forest Research Institute, a division of Forest Laboratories, Inc. Mr. Theodore J. Israel, Jr. The Hassenfeld Foundation

The Lauder Foundation - The Leonard and Evelyn Lauder Fund Ortho-McNeil Neurologics, administered by Ortho-McNeil Janssen Scientific Affairs, LLC

The Pittman Family Foundation The Price Family Foundation, Inc. The Rachel Foundation Jon & Susan Rotenstreich Foundation Mr. and Mrs. Randall Sandler Sanofi-Aventis U.S. Inc. Seabrook Foundation

Contributions of \$1,000 and above Academy for Healthcare Education, Inc.

David Schwartz Foundation

Accera, Inc. Acumen Pharmaceuticals, Inc. Alzheimer's Association Ms. Laurel Cutler

Dalio Family Foundation, Inc. Mrs. Joy Fishman Mr. and Mrs. James A. Gordon Mr. and Mrs. Barnett Helzberg, Jr. Mrs. Sale Johnson Mr. Laurence C. Leeds, Jr. Leeds Family Foundation Martek Biosciences Corporation Dr. Robert G. McNeil Merlin Foundation Samuel & Rose Mitchell Foundation Neurochem Inc. Samuel I. Newhouse Foundation, Inc. Mrs. William Nitze Pfizer Inc. Dr. and Mrs. Fred Sugar Targacept, Inc. Ms. Amy G. Treitel Mr. and Mrs. Cyrus Vance, Jr.

Contributions of \$100 and above

Mr. and Mrs. Buzz Zaino

Herring Finn Foundation

Mr. Amir Gold and Ms. Jane Gold

Mr. Edward H. Gilbert

Miss Toni Louise Katz

Ms. Sharon Kesselman

Daniel Kornblatt and Family Mr. and Mrs. Peter Krulewitch

Mrs. Judith C. Isroff Deborah Berke & Partners Architects LLP Ms. Mariorie Louer and Ms. Mary K. Bush Mr. Christopher Jones Miss Louise Cecchini Ms. Chu-Li Ms. Amy DiGeso Ms. Mary Jane Sokol Duyckinck Metal Products, Inc. Ms. Tina Smith and Mr. Jim Graf Mr. and Mrs. Aaron J. Edelstein Mr. and Mrs. Jesse S. Tarleton Mr. and Mrs. Stuart Walker Finey Family Fund of the Fidelity Charitable Gift Fund Ms. Barbara R. Zapson Jerry and Nanette Finger Foundation

Partnership Sponsored Programs PacifiCare Health Systems, Inc.* HealthCare Dimensions, Inc.*

*Payment from 2005 contractual

Ms. Stephanie Liang Magnum Logistics Inc. Jeffrey P. McKee Foundation Memory Arts, LLC Mr. Scott Miller Ms. Irma Oestreicher Mr. R. James Royer Mrs. Phyllis C. Sinatra David S. Steiner and Sylvia Steiner Charitable Trust Ms. Harriette P. Thayer Mrs. Mary R. Walker

Dr. and Mrs. Steven D. Lasser

Contributing Partners Ms. Linda Borsykowsky

Mrs. Kenneth Wilpon

Ms. Mary D. Bryning Ms. Marilyn Clark and Mr. Jaime Lopez Ms. Phyllis Drije Mrs. Tony Gawat Mrs. Rachel L. Rosato, Ms. Laura Albee and Ms. Lisa Smyth

This project, along with other partnership activities, has stimulated individuals, foundations and corporations to align with the ADDF and work in concert to find a cure. Hope is on the horizon and it is being expedited by marrying smart business strategies with philanthropic giving. Join the ADDF and become a venture philanthropist responsible for changing the health of humankind





Hope

DRIVING FORCE BEHIND ADDE'S MISSION. IT DIFFERENTIATES THIS CHARITY FROM OTHERS IN PURSUIT OF A CURE FOR AD. APPLYING BEST PRACTICES IN VENTURE CAPITAL INVESTING TO A NON-PROFIT GRANT AWARD VEHICLE HAS HAD A POSITIVE EFFECT ON THE FIELD.

When the ADDF's sister organization ISOA started utilizing program related investment grants in 1999 there were only a handful of drugs in clinical trials. Presently, 60 trials are being conducted, several of which received pre-clinical funding from ISOA. During 2006, ADDF and ISOA financed many promising programs at leading academic research centers and biotechnology companies worldwide. Along with work by numerous scientists in academia and industry, the drug development pipeline has created real opportunities for producing disease modifying therapies.

In an effort to catalyze the field, the ADDF took the ISOA model to a new level in 2006. Maximizing a successful record in biotechnology investments, the ADDF developed a separate philanthropic Fund for Alzheimer's Drug Discovery. Structured like a for-profit fund, the Fund seeks to raise \$10 million, in units of \$50,000 each, over 30 months. Fund contributors may designate a 501(c)(3) organization to receive a pro rata return on investment when scientists achieve contractual milestones. To open the Fund, \$1 million needed to be raised by April 1, 2007. By year's end, the ADDF raised \$600,000 and received \$1,200,000 in pledges. With such an enthusiastic response, it is anticipated that the Fund will open well before its deadline date.





lzheimer's affects nearly one-in-ten peop ige 65 and one-in-two age 85. The ADDF rying to fund as many scientists as possible revent this healthcare catastrophe from gro ng by discovering effective therapies. Partn ith us and together we will make this happe



rough my work with ADDF, I am now convinc

\$28,198,99

Amount to date ADDF and ISOA have awarded for 188 research programs and conferences in 12 countries.

AS A REGISTERED 501(C)(3) TAX-EXEMPT PUBLIC CHARITY, THE ADDF IS COMMITTED TO TRANSPARENCY AND ACCOUNTABILITY TO ITS PARTNERS.

The operational and financial relationship with the ISOA enables the ADDF to spend more on research grants and educational programs and less on general management and fundraising than most charities. This affiliation has especially made a difference during the start-up phase of the ADDF when the overhead expenses are generally at their highest.

According to the Charity Navigator, America's premier independent charity evaluator, the majority of 501(c)(3) organizations tend to spend approximately 75% on programs and services they provide. Concluding the second year of its founding, the ADDF is pleased to report that it spent 81% of its annual budget on research and scientific conferences, 6% above the national average.

In 2006, the ADDF and ISOA collaboratively awarded \$2.9 million in grants for 32 AD drug discovery research programs and 3 conferences worldwide.

